Plasma NfL levels and longitudinal change rates in C9orf72 and GRN-associated diseases: from tailored references to clinical applications
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Objective: Neurofilament light chain (NfL) is a promising biomarker in genetic frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). We evaluated plasma neurofilament light chain (pNfL) levels in controls, and their longitudinal trajectories in C9orf72 and GRN cohorts from presymptomatic to clinical stages. Methods: We analysed pNfL using Single Molecule Array (SiMoA) in 668 samples (352 baseline and 316 follow-up) of C9orf72 and GRN patients, presymptomatic carriers (PS) and controls aged between 21 and 83. They were longitudinally evaluated over a period of >2 years, during which four PS became prodromal/symptomatic. Associations between pNfL and clinical–genetic variables, and longitudinal NfL changes, were investigated using generalised and linear mixed-effects models. Optimal cut-offs were determined using the Youden Index. Results: pNfL levels increased with age in controls, from ~5 to~18 pg/mL (p<0.0001), progressing over time (mean annualised rate of change (ARC): +3.9%/year, p<0.0001). Patients displayed higher levels and greater longitudinal progression (ARC: +26.7%, p<0.0001), with gene-specific trajectories. GRN patients had higher levels than C9orf72 (86.21 vs 39.49 pg/mL, p=0.014), and greater progression rates (ARC:+29.3% vs +24.7%; p=0.016). In C9orf72 patients, levels were associated with the phenotype (ALS: 71.76 pg/mL, FTD: 37.16, psychiatric: 15.3; p=0.003) and remarkably lower in slowly progressive patients (24.11, ARC: +2.5%; p=0.05). Mean ARC was +3.2% in PS and +7.3% in prodromal carriers. We proposed gene-specific cut-offs differentiating patients from controls by decades. Conclusions: This study highlights the importance of gene-specific and age-specific references for clinical and therapeutic trials in genetic FTD/ALS. It supports the usefulness of repeating pNfL measurements and considering ARC as a prognostic marker of disease progression. Trial registration numbers: NCT02590276 and NCT04014673.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17
Baker, M., Mackenzie, I. R., Pickering-Brown, S. M., Gass, J., Rademakers, R., Lindholm, C., Snowden, J., Adamson, J., Sadovnick, A. D., Rollinson, S., et al. (2006) · Nature · doi:10.1038/nature05016 · Cited by 2,058
Neurofilaments as biomarkers in neurological disorders
Khalil, M., Teunissen, C. E., Otto, M., Piehl, F., Sormani, M. P., Gattringer, T., Barro, C., Kappos, L., Comabella, M., Fazekas, F., et al. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0058-z · Cited by 1,988 · cited 1×
“9–11 In particular, serum/plasma neurofilament light chain (pNfL) levels are elevated in FTD 12–16 and ALS 17–19 and appear to be efficient disease-tracking biomarkers at the clinical stage of genetic FTD/ALS.”
Cruts, M., Gijselinck, I., van der Zee, J., Engelborghs, S., Wils, H., Pirici, D., Rademakers, R., Vandenberghe, R., Dermaut, B., Martin, J.-J., et al. (2006) · Nature · doi:10.1038/nature05017 · Cited by 1,512
Neurofilament light chain as a biomarker in neurological disorders
Gaetani, L., Blennow, K., Calabresi, P., Di Filippo, M., Parnetti, L., & Zetterberg, H. (2019) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2018-320106 · Cited by 1,334
Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease
Mattsson, N., Andreasson, U., Zetterberg, H., Blennow, K., & Initiative, F. T. A. D. N. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2016.6117 · Cited by 1,070 · cited 1×
“9 14 31–33 Here, we traced pNfL dynamics across the life span with a broad representation of age classes, from <30 to >70 years, providing greater information on early and mid-adulthood. pNfL levels progressively increase with age, from ~5 pg/mL in the youngest to ~18 pg/mL in the eldest…”
Bridel, C., van Wieringen, W. N., Zetterberg, H., Tijms, B. M., Teunissen, C. E., and the NFL Group, Alvarez-Cermeño, J. C., Andreasson, U., Axelsson, M., Bäckström, D. C., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.1534 · Cited by 764
Mattsson, N., Cullen, N. C., Andreasson, U., Zetterberg, H., & Blennow, K. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.0765 · Cited by 726 · cited 1×
“This rate, concordant with other works, 11 32 33 35 may serve as a landmark for clinical studies.”
Khalil, M., Pirpamer, L., Hofer, E., Voortman, M. M., Barro, C., Leppert, D., Benkert, P., Ropele, S., Enzinger, C., Fazekas, F., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14612-6 · Cited by 572 · cited 3×
“9 14 31–33 Here, we traced pNfL dynamics across the life span with a broad representation of age classes, from <30 to >70 years, providing greater information on early and mid-adulthood. pNfL levels progressively increase with age, from ~5 pg/mL in the youngest to ~18 pg/mL in the eldest…”
Rohrer, J. D., Nicholas, J. M., Cash, D. M., van Swieten, J., Dopper, E., Jiskoot, L., van Minkelen, R., Rombouts, S. A., Cardoso, M. J., Clegg, S., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70324-2 · Cited by 538
Snowden, J. S., Rollinson, S., Thompson, J. C., Harris, J. M., Stopford, C. L., Richardson, A. M. T., Jones, M., Gerhard, A., Davidson, Y. S., Robinson, A., et al. (2012) · Brain · doi:10.1093/brain/awr355 · Cited by 523
Research works printed but not linked: 25
- 10.1016/j.neuron.2011.09.011 · DOI · Paper page
- 10.1016/j.neuron.2011.09.010 · DOI · Paper page
- Valente, 2019, Phenocopy syndrome of behavioral variant frontotemporal dementia: a systematic review, Alzheimers Res Ther, 11, 30, 10.1186/s13195-019-0483-2 · DOI · Paper page
- 10.1136/jnnp-2020-323487 · DOI · Paper page
- Cajanus, 2020, Serum neurofilament light chain in FTLD: association with C9orf72, clinical phenotype, and prognosis, Ann Clin Transl Neurol, 7, 903, 10.1002/acn3.51041 · DOI · Paper page
- Steinacker, 2017, Diagnostic and prognostic significance of neurofilament light chain NF-L, but not progranulin and S100B, in the course of amyotrophic lateral sclerosis: data from the German MND-net, Amyotroph Lateral Scler Frontotemporal Degener, 18, 112, 10.1080/21678421.2016.1241279 · DOI · Paper page
- 10.1136/jnnp-2018-318704 · DOI · Paper page
- Benatar, 2020, Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS, Neurology, 95, e59, 10.1212/WNL.0000000000009559 · DOI · Paper page
- Benatar, 2019, Neurofilaments in pre-symptomatic ALS and the impact of genotype, Amyotroph Lateral Scler Frontotemporal Degener, 20, 538, 10.1080/21678421.2019.1646769 · DOI · Paper page
- Caroppo, 2015, Lateral temporal lobe: an early imaging marker of the presymptomatic GRN disease?, J Alzheimers Dis, 47, 751, 10.3233/JAD-150270 · DOI · Paper page
- Bertrand, 2018, Early Cognitive, Structural, and Microstructural Changes in Presymptomatic C9orf72 Carriers Younger Than 40 Years, JAMA Neurol, 75, 10.1001/jamaneurol.2017.4266 · DOI · Paper page
- 10.1136/jnnp-2020-324647 · DOI · Paper page
- 10.1212/WNL.0000000000006344 · DOI · Paper page
- 10.1136/jmedgenet-2011-100699 · DOI · Paper page
- Cammack, 2019, Prospective natural history study of C9orf72 ALS clinical characteristics and biomarkers, Neurology, 93, 10.1212/WNL.0000000000008359 · DOI
- Preische, 2019, Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease, Nat Med, 25, 277, 10.1038/s41591-018-0304-3 · DOI · Paper page
- 10.1002/ana.24552 · DOI · Paper page
- Lleó, 2019, Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study, Alzheimers Dement, 15, 742, 10.1016/j.jalz.2019.01.015 · DOI · Paper page
- Gray, 2020, A multi-center study of neurofilament assay reliability and inter-laboratory variability, Amyotroph Lateral Scler Frontotemporal Degener, 21, 1, 10.1080/21678421.2020.1779300 · DOI
- Caroppo, 2014, Extensive white matter involvement in patients with frontotemporal lobar degeneration: think progranulin, JAMA Neurol, 71, 10.1001/jamaneurol.2014.1316 · DOI · Paper page
- Sudre CH , Bocchetta M , Heller C , et al . White matter hyperintensities in progranulin-associated frontotemporal dementia: a longitudinal GENFI study. Neuroimage 2019;24:102077. doi:10.1016/j.nicl.2019.102077 · DOI · Paper page
- Feneberg, 2018, Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis, Neurology, 90, e22, 10.1212/WNL.0000000000004761 · DOI · Paper page
- Fourier, 2020, A combination of total tau and neurofilaments discriminates between neurodegenerative and primary psychiatric disorders, Eur J Neurol, 27, 1164, 10.1111/ene.14247 · DOI
- 10.1136/jnnp-2020-323541 · DOI · Paper page
- Le Blanc, 2020, Faster Cortical Thinning and Surface Area Loss in Presymptomatic and Symptomatic C9orf72 Repeat Expansion Adult Carriers, Ann Neurol, 88, 113, 10.1002/ana.25748 · DOI
Cited by
Temporal order of clinical and biomarker changes in familial frontotemporal dementia
Staffaroni, A. M., Quintana, M., Wendelberger, B., Heuer, H. W., Russell, L. L., Cobigo, Y., Wolf, A., Goh, S.-Y. M., Petrucelli, L., Gendron, T. F., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01942-9 · Cited by 140
Self-citationGendron, T. F., Heckman, M. G., White, L. J., Veire, A. M., Pedraza, O., Burch, A. R., Bozoki, A. C., Dickerson, B. C., Domoto-Reilly, K., Foroud, T., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100607 · Cited by 70
Das, S., Dewit, N., Jacobs, D., Pijnenburg, Y. A. L., In ‘t Veld, S. G. J. G., Coppens, S., Quaglia, M., Hirtz, C., Teunissen, C. E., & Vanmechelen, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137221 · Cited by 26
“An increase in CSF Nf-L levels in an individual over time is inherent to normal aging, and, in line with previous findings, we reported in this cohort that Nf-L levels increased with the increasing age of patients [13,30,31].”
ResultSheth, U., Öijerstedt, L., Heckman, M. G., White, L. J., Heuer, H. W., Lario Lago, A., Forsberg, L. K., Faber, K. M., Foroud, T. M., Rademakers, R., et al. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00821-4 · Cited by 20
The role of neurofilament light in genetic frontotemporal lobar degeneration
Zetterberg, H., Teunissen, C., van Swieten, J., Kuhle, J., Boxer, A., Rohrer, J. D., Mitic, L., Nicholson, A. M., Pearlman, R., McCaughey, S. M., et al. (2022) · Brain Communications · doi:10.1093/braincomms/fcac310 · Cited by 19
“Furthermore, higher baseline NfL correlated with worse longitudinal clinical measures and brain atrophy in all FTD genetic mutation types, arguing that blood-based NfL is predictive of short-term risk for FTD disease progression.3,4,73,74 Longitudinal changes in plasma NfL in presymptomatic and symptomatic GRN and C9o…”
Method
Metadata
- Authors
- Saracino, D., Dorgham, K., Camuzat, A., Rinaldi, D., Rametti-Lacroux, A., Houot, M., Clot, F., Martin-Hardy, P., Jornea, L., Azuar, C., Migliaccio, R., Pasquier, F., Couratier, P., Auriacombe, S., Sauvée, M., Boutoleau-Bretonnière, C., Pariente, J., Didic, M., Hannequin, D., Wallon, D., the French Research Network on FTD/FTD-ALS, groups, T. P.-D. A. P.-P. S., Colliot, O., Dubois, B., Brice, A., Levy, R., Forlani, S., & Le Ber, I.
- Venue
- Journal of Neurology, Neurosurgery & Psychiatry
- Publisher
- BMJ
- Published
- 2021-08-04
- Volume
- 92
- Issue
- 12
- Pages
- 1278-1288
- ISSN
- 0022-3050 (ISSN-L)
- 1468-330X
- OpenAlex
- W3188822439
- Cited by
- 55
- References
- 19
- FWCI
- 3.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Funders
- Programme Hospitalier de Recherche Clinique (FTLD-exome, Predict-PGRN)
- Agence Nationale de la Recherche (ANR-PRTS PREV-DEMALS, “Investissements d’avenir” ANR-11-INBS-0011)
- Fondation Vaincre Alzheimer (FR-17035)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Plasma NfL levels and longitudinal change rates in C9orf72 and GRN-associated diseases: from tailored references to clinical applications. https://app.cochat.ai/papers/10.1136/jnnp-2021-326914
- The paper
- Saracino, D., Dorgham, K., Camuzat, A., Rinaldi, D., Rametti-Lacroux, A., Houot, M., Clot, F., Martin-Hardy, P., Jornea, L., Azuar, C., Migliaccio, R., Pasquier, F., Couratier, P., Auriacombe, S., Sauvée, M., Boutoleau-Bretonnière, C., Pariente, J., Didic, M., Hannequin, D., . . . Le Ber, I. (2021). Plasma NfL levels and longitudinal change rates in C9orf72 and GRN-associated diseases: from tailored references to clinical applications. Journal of Neurology, Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp-2021-326914
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.